Citigroup’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Citigroup’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,624	Closed	-$12.1K	–	5895
2023 Q4	$12.1K	Sell	1,624 -3,643	-69%	-$23.7K	﹤0.01%	5144
2023 Q3	$30.3K	Buy	+5,267	New	+$36K	﹤0.01%	4280
2022 Q3	–	Sell	-9	Closed	–	–	6448
2022 Q2	$0	Sell	9 -244	-96%	-$3.86K	﹤0.01%	6774
2022 Q1	$5K	Buy	253 +8	+3%	+$277	﹤0.01%	5847
2021 Q4	$15K	Buy	245 +125	+104%	+$9.35K	﹤0.01%	5482
2021 Q3	$11K	Buy	120 +74	+161%	+$9.86K	﹤0.01%	5451
2021 Q2	$8K	Sell	46 -12	-21%	-$2.04K	﹤0.01%	5749
2021 Q1	$11K	Buy	+58	New	+$14.5K	﹤0.01%	5606

Other funds holding TLIS

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup's TLIS Position: Q1 2024 in Review

Citigroup sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q1 2024, closing a stake of 1,624 shares — an estimated $12.1K sold.

Citigroup first reported a position in TLIS in Q1 2021 and held it in 8 quarters. The position peaked at $30.3K in Q3 2023. 18 funds tracked by Wall St. Rank hold TLIS as of Q1 2024.

Citigroup reported no remaining Talis Biomedical Corporation Common Stock position as of Q1 2024 after selling out during the quarter.
Citigroup sold 1,624 Talis Biomedical Corporation Common Stock shares in Q1 2024, an estimated $12.1K.
Citigroup first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 8 quarters.
Citigroup's Talis Biomedical Corporation Common Stock position peaked at $30.3K in Q3 2023.
18 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q1 2024.

Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.